Propofol and Magnesium Sulfate Intravenous Infusion During Endoscopic Sinus Surgery

Sponsor
Mansoura University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04078659
Collaborator
(none)
50
1
2
5
9.9

Study Details

Study Description

Brief Summary

Endoscopic Sinus surgery usually associated by bleeding, despite using of local vasopressor injection, head up position- controlled hypotension is generally used for control of this purpose.

Propofol has been reported as a good agent for controlled hypotension by decreasing systemic vascular resistance secondary to arterial and venous vasodilation and a decrease in myocardial contractility with a dose-dependent property.

Magnesium Sulfate also has been reported as an agent of hypotensive anaesthesia by inhibition of the release of norepinephrine by blocking N-type calcium channel at the nerve ending beside acting as a vasodilator.

The well known pharmacodynamic effects of the intravenous infusion of propofol or Magnesium Sulfate may prove the advantage of this group in controlling intraoperative blood pressure thus reducing surgical field bleeding.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

The aim of the work to compare the efficacy of propofol and magnesium sulfate to control blood pressure during endoscopic sinus surgery and the resultant effects on the quality of the surgical field including bleeding and visibility.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Controlled Hypotension During Endoscopic Sinus Surgery: A Comparison of Propofol and Magnesium Sulfate
Anticipated Study Start Date :
Sep 1, 2019
Anticipated Primary Completion Date :
Jan 1, 2020
Anticipated Study Completion Date :
Feb 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Propofol infusion

Patients received intravenous Propofol infusion

Drug: Propofol infusion
Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)

Drug: Lidocaine
Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia

Drug: Fentanyl
Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia

Drug: Propofol
Patients will receive propofol in a dose of 1-2 mg /kg

Drug: Atracurium
Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation

Procedure: Mechanical Ventilation
Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute

Experimental: Magnesium Sulfate infusion

Patients received intravenous Magnesium Sulfate infusion

Drug: Magnesium Sulfate infusion
Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia

Drug: Lidocaine
Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia

Drug: Fentanyl
Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia

Drug: Propofol
Patients will receive propofol in a dose of 1-2 mg /kg

Drug: Atracurium
Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation

Procedure: Mechanical Ventilation
Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute

Outcome Measures

Primary Outcome Measures

  1. Mean arterial blood pressure (MAP) [15 minutes after the induction of the hypotensive agent]

    automatically non invasive measured every 3 minutes , recorded every 15 minutes till the end and 15 minutes after extubation the end and 15 minutes after extubation

Secondary Outcome Measures

  1. The blood loss [at the end of the surgery]

    The blood loss would be calculated using the following formula Blood Loss = Blood Volume. In )Hct 1 / Hct2)

  2. The number of patients will need nitroglycerine and dose [at the end of the surgery]

    The number of patients will need nitroglycerine

  3. Use of Ephedrine [at the end of the surgery]

    The number of patients will need ephedrine

  4. Need for blood transfusion [at the end of the surgery]

    The number of patient need for blood transfusion

  5. Postoperative Ramsey sedation [for the first hour postoperative]

    patient awake, anxious, agitated or restless 2 patient awake -1co operative, oriented and tranquil 3 patient drowsy with respond to command 4 patient asleep brisk response to glabella tap or loud auditory sound 5 patient asleep with sluggish response to stimulus 6 patient hasno response to nail bed pressure or othernoxious stimuli

  6. Simplified post operative nausea and vomiting score [for the first 24 hour postoperative]

    using impact scale score evaluation

  7. Recovery time [one hour after extubation]

    time needed to reach modified aldrete score> or=9)

  8. Heart rate (HR) [15 minutes after the start of the hypotensive agent]

  9. surgical field assessment [2 hours intraoperative]

    By the surgeon interms of bleeding and visibility using a 6-option Liker-scale scale adapted from Fromme el al. (26): 0 = no bleeding; 1 = minor bleeding, but no aspiration required; 2 = minor bleeding, aspiration required; 3 = minor bleeding, frequent aspiration required; 4 = moderate bleeding, visible� only with aspiration; 5 = severe bleeding, continuous aspiration required

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists Physical Classes I or II
Exclusion Criteria:
  • Patients refusal

  • Patients with hypersensitivity for any drug used in the study including magnesium, propofol or isoflurane

  • Patients receiving magnesium sulfate supplementation

  • Patients receiving drugs known to have significant interaction.

  • Patients with ischemic heart disease

  • Patients with heart defects

  • Patients with significant heart failure

  • Patients with increased intracranial pressure.

  • Patients with systemic hypertension

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nabil A Abd El-Mageed Mansoura DK Egypt 050

Sponsors and Collaborators

  • Mansoura University

Investigators

  • Study Director: Hazem E Moawed, Assistant Professor of Anesthesia and Surgical Intensive Care

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mansoura University
ClinicalTrials.gov Identifier:
NCT04078659
Other Study ID Numbers:
  • MS ∕18.08.247
First Posted:
Sep 6, 2019
Last Update Posted:
Sep 6, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 6, 2019